192
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B—A Retrospective Cohort Study

, ORCID Icon, , , , , & show all
Pages 2311-2322 | Published online: 02 Aug 2022

Figures & data

Table 1 Baseline Characteristics of Patients Before and After IPTW

Figure 1 Flowchart of the study cohorts.

Figure 1 Flowchart of the study cohorts.

Figure 2 Metabolic characteristics of patients in the CHB-MAFLD group. In the CHB-MAFLD group, the proportions of patients with BMI ≥ 23 kg/m2, with BMI < 23 kg/m2 and metabolic dysfunctions, with BMI < 23 kg/m2 and DM were 85.64%, 11.83%, and 2.53%, respectively (A), while 82.53% of these CHB-MAFLD patients had at least one metabolic risk factor (B).

Figure 2 Metabolic characteristics of patients in the CHB-MAFLD group. In the CHB-MAFLD group, the proportions of patients with BMI ≥ 23 kg/m2, with BMI < 23 kg/m2 and metabolic dysfunctions, with BMI < 23 kg/m2 and DM were 85.64%, 11.83%, and 2.53%, respectively (A), while 82.53% of these CHB-MAFLD patients had at least one metabolic risk factor (B).

Figure 3 Cumulative incidence of cirrhosis per year after IPTW. The different weighted cumulative incidence of cirrhosis per year between the CHB-MAFLD group and the CHB group after IPTW.

Figure 3 Cumulative incidence of cirrhosis per year after IPTW. The different weighted cumulative incidence of cirrhosis per year between the CHB-MAFLD group and the CHB group after IPTW.

Figure 4 Cumulative incidence of cirrhosis after IPTW. The cumulative incidence of cirrhosis in the CHB-MAFLD group was significantly higher than that in the CHB group (12.6% and 7.1%, respectively, P=0.015).

Figure 4 Cumulative incidence of cirrhosis after IPTW. The cumulative incidence of cirrhosis in the CHB-MAFLD group was significantly higher than that in the CHB group (12.6% and 7.1%, respectively, P=0.015).

Figure 5 Cumulative incidence of cirrhosis after IPTW, by antiviral treatment status.

Notes: (A) Patients without antiviral treatment. (B) Patients with antiviral treatment. The weighted cumulative incidence of cirrhosis was significantly higher in the CHB-MAFLD group compared to the CHB group, whether in patients without antiviral treatment (A) or in patients with antiviral treatment (B).
Figure 5 Cumulative incidence of cirrhosis after IPTW, by antiviral treatment status.

Table 2 Weighted Univariate and Multivariate Cox Analysis of Risk Factors Related to Cirrhosis After IPTW

Figure 6 Subgroup analysis of cirrhosis risk after IPTW, by antiviral treatment status.

Notes: (A) All patients. (B) Patients with alcohol consumption are excluded. MAFLD was associated with an increased risk of cirrhosis in CHB patients receiving or not receiving antiviral therapy, whether in all patients (A) or in patients without alcohol use (B).
Figure 6 Subgroup analysis of cirrhosis risk after IPTW, by antiviral treatment status.